Oakridge Reports $770K Quarterly Receipts and Legal Claim Update

Revenue Growth and Operational Momentum

Oakridge International Limited (ASX:OAK) continued to build on its healthcare technology footprint during the quarter ended 30 June 2026, with cash receipts from customers hitting $770,000 and a full-year total of $2.962 million, up from $2.458 million in the prior year. The company’s core offerings, nurse call and assistive technology solutions, saw steady project delivery and partner-led sales activity across hospitals, aged care, disability care, and supported independent living.

Project work remained robust, with multiple installations progressing through programming, component delivery, commissioning, and installation phases. The active quote book is substantial, spanning diverse sectors and geographies, supporting a pipeline of opportunities that management expects will convert to revenue in FY2027.

Product Development Advances and System Improvements

Oakridge pushed forward with its real-time location system (RTLS) upgrades, completing call point and resident pendant orders. Enterprise platform development reached a milestone with first-stage enterprise reporting completed and demonstrated. Mobile application development and firmware refinements for annunciator products continued, focusing on reliability and user functionality.

Internal operational improvements also featured prominently, including alignment of systems for better workflow, inventory visibility, and reporting accuracy. The company is preparing for ISO 9001:2015 and ISO 27001 certification, reflecting its emphasis on quality and information security readiness.

Capital and Related Party Transactions

During the quarter, Oakridge raised $349,996 from the exercise of options by Montague Capital Pty Ltd, linked to director Con Unerkov. Related party payments of approximately $108,000 were made, covering director and executive officer fees. Financing activities resulted in a net cash inflow of $73,000, contributing to a healthy cash balance of $638,000 at quarter end.

Legal Exposure and Industry Engagement

The company reiterated ongoing discussions with Teko International Limited regarding a potential claim over alleged misrepresentations by previous directors concerning unrecorded liabilities. While the board acknowledges some exposure, the outcome and financial impact remain uncertain. Oakridge continues to engage legal advisors to seek a favourable resolution.

Marketing efforts and industry engagement remained active, with brand visibility enhanced through digital marketing, website refreshes, and conference participation. Strategic partner activity across multiple states supported project opportunities and market coverage, underpinning future revenue potential.

Exploring AI and Future Opportunities

Looking ahead, Oakridge is evaluating complementary product opportunities, including AI-related applications aimed at improving documentation, quality reporting, compliance, and operational efficiency. These initiatives remain in early stages of assessment and development but align with the company’s strategy to expand its healthcare technology offerings.